Printer Friendly

ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION

 BETHESDA, Md., March 1 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) and Sclavo, S.p.A. of Siena, Italy announced today that Sclavo will build, at Sclavo's expense, a Thymosin alpha 1 manufacturing facility in Italy. This facility, which will be built based on manufacturing technology developed by Alpha 1, will produce annually sufficient Thymosin alpha 1 to treat 100,000 patients with chronic hepatitis B. Alpha 1 and Sclavo will share equally in the manufacturing profits from Thymosin alpha 1 manufactured by Sclavo. It is expected that the facility could be operational by the end of 1994.
 Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 stated "We are very pleased with the decision by Sclavo to substantially increase its investment in Thymosin alpha 1. Alpha 1 Biomedicals will be able to supply its other licensees from this facility, if needed." Dr. Simon also noted that "Alpha 1 has recently identified additional space in California to substantially expand its domestic manufacturing capability. Construction on our facility in California will proceed as resources permit."
 Sclavo-sponsored clinical trials in Italy are in progress using Thymosin for the treatment of chronic hepatitis B and C, cancer (melanoma, non-small cell lung carcinoma, hepatocellular carcinoma) and AIDS. Thymosin alpha 1 has been reviewed and approved for safety and efficacy for certain indications by the Italian Ministry of Health but is not yet approved for sales in Italy. A five center trial in Italy using Thymosin alpha 1 for the treatment of chronic hepatitis B is expected to be completed in mid-1993. If the trial is successful, the approval for chronic hepatitis B indication could occur by mid-1994 in Italy.
 Thymosin alpha 1 is currently in an Alpha 1-sponsored multi-center Phase III trial for the treatment of chronic hepatitis B in the U.S. Alpha 1 is also sponsoring U.S. clinical trials with Thymosin alpha 1 with other drugs for the treatment of chronic active hepatitis C and AIDS.
 -0- 3/1/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals, Inc./
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

AH-TS -- NY029 -- 1300 03/01/93 10:12 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:379
Previous Article:AIR CANADA WILL CHANGE TERMINALS AT LAGUARDIA
Next Article:ZWEIG TOTAL RETURN FUND, INC. DECLARES MONTHLY DISTRIBUTION
Topics:


Related Articles
ALPHA 1 BIOMEDICALS, INC. REPORTS THIRD QUARTER CALENDAR YEAR 1992 RESULTS
U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS
ALPHA 1 BIOMEDICALS ANNOUNCES REVISIONS TO TERMS OF THE REDEMPTION OF ITS CLASS B WARRANTS
ALPHA 1 BIOMEDICALS, INC. FOURTH QUARTER AND CALENDAR YEAR 1992 RESULTS
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES PUBLICATION OF PRICE APPROVAL OF THYMOSIN ALPHA 1 IN ITALY
ENROLLMENT COMPLETED IN ALPHA 1 BIOMEDICALS' PHASE III CLINICAL TRIAL
UPDATE ON HGP-30 AIDS VACCINE PRESENTED AT BERLIN AIDS CONFERENCE
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
ICN BIOMEDICALS REPORTS FIRST QUARTER EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters